Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ANXA1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
ANXA1 is a protein involved in neurodegeneration research. Key relationships include: regulates, contributes to, activates. Associated with ALS, Acute Ischemic Stroke, Aging. Connected to 189 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | ANXA1 |
| Full Name | Annexin A1 |
| Chromosome | 9q21.13 |
| Target Class | Signaling Protein |
| Function | ANXA1 performs diverse cellular functions: |
| Mechanism of Action | Calcium-dependent phospholipid binding protein modulator |
| Primary Expression | the nervous system: |
| Druggability | Low (0.41) |
| Clinical Stage | Approved |
| Molecular Weight | ~37 kDa |
| Amino Acids | 346 aa |
| Exons | 13 |
| Pathways | Apoptosis, Blood-Brain Barrier, Immune Response, Mtor, cGAS/STING Pathway |
| UniProt ID | P04083 |
| NCBI Gene ID | 303 |
| Ensembl ID | ENSG00000109255 |
| OMIM | 151690 |
| GeneCards | ANXA1 |
| Human Protein Atlas | ANXA1 |
| Associated Diseases | aging, ALS, Alzheimer, cancer |
| Known Drugs/Compounds | aducanumab, GW201, Tat-Nts, Tat-NTS, Tat-NTS peptide |
| Interactions | AKT, AMPK, AND, APOPTOSIS, AUTOPHAGY, BECN1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Synaptic Phosphatidylserine Masking via Annexin A1 |
| KG Connections | 528 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
ANXA1["ANXA1"] -->|"associated"| Efferocytosis["Efferocytosis"]
ANXA1["ANXA1"] -->|"expressed in"| CD68__Macrophages["CD68+ Macrophages"]
ANXA1["ANXA1"] -->|"regulates"| cGAS_STING_Pathway["cGAS/STING Pathway"]
ANXA1["ANXA1"] -->|"biomarker for"| Pancreatic_Cancer["Pancreatic Cancer"]
ANXA1["ANXA1"] -->|"associated"| Antitumor_Immune_Responses["Antitumor Immune Responses"]
ANXA1["ANXA1"] -->|"biomarker for"| bladder_cancer["bladder cancer"]
h_513a633f["h-513a633f"] -->|"targets"| ANXA1["ANXA1"]
CASP3["CASP3"] -->|"associated"| ANXA1["ANXA1"]
JUN["JUN"] -->|"therapeutic target"| ANXA1["ANXA1"]
TNF["TNF"] -->|"therapeutic target"| ANXA1["ANXA1"]
style ANXA1 fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Leukocyte-Mediated Immune Response | regulates | process | 0.95 |
| Efferocytosis | associated_with | process | 0.95 |
| Macrophage Efferocytosis | regulates | process | 0.95 |
| Macrophages | expressed_in | cell_type | 0.95 |
| MICROGLIA | modulates | cell_type | 0.95 |
| Leukocyte-Mediated Immune Response | inhibits | process | 0.95 |
| Cgas/Sting Pathway | inhibits | pathway | 0.95 |
| Inflammation | inhibits | process | 0.95 |
| Efferocytosis | promotes | process | 0.95 |
| Cd68+ Macrophages | expressed_in | cell_type | 0.95 |
| Microglia/Macrophage Polarization | modulates | process | 0.95 |
| Cerebral Ischemia-Reperfusion Injury | protects_against | disease | 0.95 |
| myocardial membrane repair | mediates | process | 0.95 |
| donation after circulatory death complications | therapeutic_target | disease | 0.92 |
| CD68+ Macrophages | expressed_in | cell_type | 0.92 |
| INFLAMMATION | inhibits | process | 0.92 |
| Tumor Growth | promotes | phenotype | 0.92 |
| Pro-Inflammatory Macrophages | upregulates | cell_type | 0.90 |
| Microglia Polarization | modulates | process | 0.90 |
| leukocyte-mediated immune responses | inhibits | process | 0.90 |
| Effector T Cells | upregulates | cell_type | 0.90 |
| Macrophage Polarization | modulates | process | 0.90 |
| warm ischemic injury | protects_against | phenotype | 0.90 |
| Sumoylation | involved_in | process | 0.90 |
| PI3K/AKT pathway | activates | pathway | 0.90 |
| Apoptotic Cell Accumulation | inhibits | phenotype | 0.90 |
| cGAS/STING Pathway | regulates | pathway | 0.90 |
| macrophage | modulates | cell_type | 0.90 |
| inflammation | suppresses | process | 0.90 |
| Pancreatic Cancer | associated_with | disease | 0.90 |
| Apoptosis | inhibits | process | 0.90 |
| Anti-Inflammatory Response | promotes | process | 0.88 |
| Survival | biomarker_for | phenotype | 0.88 |
| Plasma Membrane Repair | mediates | process | 0.88 |
| Ischemic Injury | biomarker_for | phenotype | 0.85 |
| Central Inflammation | modulates | process | 0.85 |
| Blood-Brain Barrier Integrity | modulates | process | 0.85 |
| FPR2 | binds | receptor | 0.85 |
| Homeostasis | associated_with | process | 0.85 |
| Hormonal Secretion | modulates | process | 0.85 |
| Pancreatic Cancer | biomarker_for | disease | 0.85 |
| Blood-Brain Barrier Integrity | involved_in | process | 0.85 |
| Endocrine Control | modulates | process | 0.85 |
| Hormonal Secretion | regulates | process | 0.85 |
| Immune Repair | involved_in | process | 0.85 |
| Efferocytosis | regulates | process | 0.85 |
| Cellular Signalling | modulates | process | 0.85 |
| Peripheral Inflammation | modulates | process | 0.85 |
| Microglial Activation | regulates | process | 0.85 |
| Nuclear Localization | involved_in | process | 0.85 |
| Source | Relation | Type | Str |
|---|---|---|---|
| MIR374B | downregulates | gene | 0.95 |
| Tat-Nts | targets | drug | 0.95 |
| Cd68+ Macrophages | expressed_in | cell_type | 0.92 |
| Tat-NTS | targets | drug | 0.90 |
| Tat-NTS peptide | binds | drug | 0.90 |
| h-513a633f | targets_gene | hypothesis | 0.90 |
| warm ischemic time | downregulates | process | 0.90 |
| LINC00491 | upregulates | gene | 0.90 |
| PURA | inhibits | protein | 0.85 |
| GW201 | modulates | compound | 0.85 |
| ALX | binds | receptor | 0.85 |
| FPR2 | binds | receptor | 0.85 |
| Purα | inhibits | protein | 0.85 |
| cGAS/STING Pathway | activates | pathway | 0.80 |
| h-513a633f | targets | hypothesis | 0.80 |
| MICROGLIA | SUMOylates | cell_type | 0.80 |
| TAT-NTS | promotes_SUMOylation_of | compound | 0.80 |
| GW201 | upregulates | compound | 0.75 |
| AND | activates | gene | 0.60 |
| BECN1 | modulates | gene | 0.60 |
| CANCER | implicated_in | gene | 0.60 |
| ALZHEIMER'S DISEASE | implicated_in | gene | 0.60 |
| DEPRESSION | implicated_in | gene | 0.60 |
| AND | contributes_to | gene | 0.60 |
| ALZHEIMER | implicated_in | gene | 0.60 |
| CGAS-STING | inhibits | gene | 0.60 |
| CANCER | activates | gene | 0.60 |
| AGING | transports | gene | 0.60 |
| TNF | therapeutic_target | gene | 0.60 |
| NBR1 | activates | gene | 0.60 |
| CX3CR1 | therapeutic_target | gene | 0.60 |
| NTS | protects_against | gene | 0.60 |
| MTOR | regulates | gene | 0.60 |
| CD68 | expressed_in | gene | 0.60 |
| CGAS | inhibits | gene | 0.60 |
| STING | activates | gene | 0.60 |
| ANXA2 | contributes_to | gene | 0.60 |
| OVERVIEW | regulates | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
| CASP3 | associated_with | gene | 0.60 |
| JUN | therapeutic_target | gene | 0.60 |
| IL-1 | therapeutic_target | gene | 0.60 |
| DEPRESSION | therapeutic_target | gene | 0.60 |
| ALZHEIMER | therapeutic_target | gene | 0.60 |
| CANCER | contributes_to | gene | 0.60 |
| CX3CR1 | activates | gene | 0.60 |
| JUN | contributes_to | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| AKT | expressed_in | gene | 0.60 |
| AKT | regulates | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | 0.680 | neurodegeneration | Synaptic pruning by microglia in early A |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.739
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune mi [PMID:39237260] | Hou Z, Lu F, Lin J, Wu Y, Chen L, Fang H | J Immunother Cancer | 2024 | 1 |
| The role of annexins in central nervous system development and disease. [PMID:38639785] | White ZB 2nd, Nair S, Bredel M | J Mol Med (Berl) | 2024 | 1 |
| Tat-NTS peptide protects neurons against cerebral ischemia-reperfusion injury vi [PMID:37908731] | Zhou H, Yan L, Huang H, Li X, Xia Q, Zhe | Theranostics | 2023 | 1 |
| Annexin A1 protects against cerebral ischemia-reperfusion injury by modulating m [PMID:34022892] | Xu X, Gao W, Li L, Hao J, Yang B, Wang T | J Neuroinflammation | 2021 | 1 |
| Annexin A1: Uncovering the Many Talents of an Old Protein. [PMID:29614751] | Sheikh MH, Solito E | Int J Mol Sci | 2018 | 1 |
| LINC00491 promotes nasopharyngeal carcinoma metastasis by binding to purine-rich [PMID:41903631] | ["Liu Y", "Li H", "Zhang J", "Peng J", " | International journal of biolo | 2026 | 0 |
| GW201 mediates neuroprotection via allosteric modulation of NMDA receptor activi [PMID:41693050] | ["Tiliwaerde M", "Zhaoji D", "Jingjing L | British journal of pharmacolog | 2026 | 0 |
| Annexin A1 enhances liver repair after acetaminophen-induced liver injury by reg [PMID:41707743] | ["Zha L", "Liu D", "Zhan M", "Xu Y", "Ha | Free radical biology & medicin | 2026 | 0 |
| Myeloid cell-specific β2-adrenergic receptor deletion improves early cardiac inj [PMID:41695468] | ["Nayak T", "Bajpai A", "Patwa V", "Cart | Theranostics | 2026 | 0 |
| Sex-specific hypothalamic PVN transcriptomic signatures of blood pressure autono [PMID:41723507] | ["Duque V", "Nani J", "Jovanovic M", "Lo | Biology of sex differences | 2026 | 0 |
| Attenuated crosstalk between urothelium and fibroblasts promotes ureteral strict [PMID:41924262] | ["Guo R", "Zhang X", "Wang C", "Cui J", | Frontiers in immunology | 2026 | 0 |
| AnnexinA1-Dectin 1 axis is a key regulator of osteoclastogenesis underlying irra [PMID:41925240] | ["Guliyeva G", "Takile F", "Stallfort V" | Journal of bone and mineral re | 2026 | 0 |
| Characterization of ANXA1 in chemotherapy resistance of head and neck squamous c [PMID:41836290] | ["Zheng L", "Yang H", "Cheng Y", "Xia B" | Frontiers in cell and developm | 2026 | 0 |
| The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cel [PMID:40683881] | ["Doroszko M", "Stockgard R", "Uppman I" | Nature communications | 2025 | 0 |
| Loss of Endothelial Annexin A1 Aggravates Inflammation-Induched Vascular Aging. [PMID:38358087] | You Q, Ke Y, Chen X, Yan W, Li D, Chen L | Advanced science (Weinheim, Ba | 2024 | 0 |
| Anxa1 in smooth muscle cells protects against acute aortic dissection. [PMID:33757117] | Zhou C, Lin Z, Cao H, Chen Y, Li J, Zhua | Cardiovascular research | 2022 | 0 |
| Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances th [PMID:33799527] | ["Huang K", "Chiang S", "Yang P", "Ke T" | Cancers | 2021 | 0 |
| Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in [PMID:30972066] | ["Purvis G", "Collino M", "Loiola R", "B | Frontiers in immunology | 2019 | 0 |
| Annexin A1-derived peptide Ac [PMID:30755225] | ["Gimenes A", "Andrade B", "Pinotti J", | Journal of neuroinflammation | 2019 | 0 |
| Annexins-Coordinators of Cholesterol Homeostasis in Endocytic Pathways. [PMID:29757220] | Rentero C, Blanco-Muñoz P, Meneses-Salas | International journal of molec | 2018 | 0 |
Multi-agent debates referencing this entity